Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation

Summary In young and fit patients with mantle cell lymphoma (MCL), intensive induction therapy followed by a consolidative autologous haematopoietic cell transplant (autoHCT) is the standard of care in the front‐line setting. Recently, time‐to‐event analysis has emerged as an important risk assessme...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2021-12, Vol.195 (5), p.757-763
Main Authors: Riedell, Peter A., Hamadani, Mehdi, Ahn, Kwang W., Litovich, Carlos, Brunstein, Claudio G., Cashen, Amanda F., Cohen, Jonathon B., Epperla, Narendranath, Hill, Brian T., Im, Annie, Inwards, David J., Lister, John, McCarty, John M., Ravi Kiran Pingali, Sai, Shadman, Mazyar, Shaughnessy, Paul, Solh, Melhem, Stiff, Patrick J., Vose, Julie M., Kharfan-Dabaja, Mohamed A., Herrera, Alex F., Sauter, Craig S., Smith, Sonali M.
Format: Article
Language:English
Subjects:
Adult
Aged
Autografts
autologous transplant
dynamic landmark analysis
Female
Hematology
Hematopoietic Stem Cell Transplantation
Humans
Induction therapy
Lymphoma
Lymphoma, Mantle-Cell - diagnosis
Lymphoma, Mantle-Cell - therapy
Male
Mantle cell lymphoma
Middle Aged
Multivariate analysis
Neoplasm Recurrence, Local - diagnosis
Retrospective Studies
Risk assessment
Survival Analysis
Time Factors
time to relapse
Transplantation
Transplantation, Autologous
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary In young and fit patients with mantle cell lymphoma (MCL), intensive induction therapy followed by a consolidative autologous haematopoietic cell transplant (autoHCT) is the standard of care in the front‐line setting. Recently, time‐to‐event analysis has emerged as an important risk assessment tool in lymphoma, though its impact in MCL is not well defined. We utilized the Center for International Blood and Marrow Transplant Research database to evaluate the effect of post‐autoHCT time to relapse on overall survival (OS) over time in 461 patients who underwent autoHCT within 12 months of MCL diagnosis. On multivariate analysis, the impact of relapse on OS was greatest at the six‐month [hazard ratio (HR) = 7·68], 12‐month (HR = 6·68), and 18‐month (HR = 5·81) landmark timepoints. Using a dynamic landmark model we demonstrate that adjusted OS at five years following each landmark timepoint improved with time for relapsing and non‐relapsing patients. Furthermore, early relapse (
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.17865